(PFE:OMX Nordic Exchange Stockholm)
Transactions by PFIZER INC (PFE) in the last 6 months
Pfizer Inc. (NYSE:PFE) entered into a definitive merger agreement to acquire Hospira Inc. (NYSE:HSP) for $15.4 billion in cash on February 5, 2015. Under the terms, each outstanding share of Hospira will be converted into the right to receive $90 per share in cash. Each outstanding Hospira stock option, restricted stock unit, performance share award, performance restricted stock unit and restricted share will be cancelled and converted into the right to receive the consideration ...
NovaQuest Healthcare Investment Fund, L.P.
T. Rowe Price Associates, Inc.
Pfizer Inc. (NYSE:PFE) acquired a controlling stake in Redvax GmbH from Redbiotec AG on January 5, 2015.
Pfizer Inc. (NYSE:PFE) entered into an agreement to acquire worldwide licenses of hGH-CTP from Opko Health, Inc. (NYSE:OPK) for $570 million on December 13, 2014. Under the terms of the agreement, Opko Health will receive an upfront payment of $295 million and is eligible to receive up to an additional $275 million upon the achievement of certain regulatory milestones. Pfizer will receive the exclusive license to commercialize hGH-CTP worldwide. The transaction is subject ...
iTeos Therapeutics SA announced that it will receive equity funding from Pfizer Inc. on December 8, 2014.
Pfizer Inc. (NYSE:PFE) announces a share repurchase program. Under the program, the company will repurchase up to $11 billion worth of its shares. The plan will be utilized over time.
The Board of Directors of Pfizer Inc. has authorized a buyback plan on October 23, 2014.
On October 23, 2014, the company initiated a Market Repurchase.
From October 23, 2014 to January 27, 2015, the company has repurchased 6,393,267 shares, representing 0.1% for $199.46 million. ...
|Merck & Co Inc||$57.88 USD||-0.46|
|Nestle SA||SFr.75.40 CHF||+0.80|
|Novartis AG||SFr.95.20 CHF||+0.20|
|Roche Holding AG||SFr.260.20 CHF||+0.20|
|Procter & Gamble Co/The||$84.35 USD||-0.81|
|View Industry Companies|